<DOC>
	<DOC>NCT00254540</DOC>
	<brief_summary>To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).</brief_summary>
	<brief_title>Study of SU011248 in Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven renal cell carcinoma with metastases with a component of clear cell histology Any cellular therapy (LAK, TIL, DC), any vaccine therapy, minitransplantation, or systemic moleculartargeting therapy for RCC.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Ph2, RCC, SU011248, SUNITINIB</keyword>
</DOC>